Table 1.

Patient characteristics

Patient	Age (years)	BMI (kg/m2)	Tamoxifen dose (mg)	Setting	Mental disordera	First antidepressant and doseb	Second antidepressant and dose	CYP2D6 genotype
1	43	24.1	20	Adjuvant	Depressive disorder	Paroxetine 15 mg	Escitalopram 15 mg	*1/*1 (EM)
2	54	23.0	20	Adjuvant	Depressive disorder	Paroxetine 60 mg	Escitalopram 20 mg	*1/*1 (EM)
3	49	32.9	20	Adjuvant	Depressive disorder	Paroxetine 20 mg	Citalopram 10 mgc	*1/*1 (EM)
4	43	29.4	20	Adjuvant	Anxiety disorder	Paroxetine 20 mg	Escitalopram 10 mg	*1/*4 (IM)
5	55	33.6	20	Adjuvant	Anxiety disorder	Fluoxetine 20 mg	Escitalopram 10 mg	*1/*1 (EM)
6d	48	45.2	40e	Adjuvant	Depressive disorder	Paroxetine 20 mg	Escitalopram 10 mg	*1/*1 (EM)
7	59	26.4	20	Adjuvant	Anxiety disorder	Paroxetine 20 mg	Escitalopram 10 mg	NA
8	41	29.3	40	Metastatic	Depressive disorder	Fluoxetine 30 mg	Escitalopram 10 mg	*1/*1 (EM)
9	53	30.7	20	Adjuvant	Anxiety disorder	Paroxetine 40 mg	Escitalopram 10 mg	*4/*41 (IM)
10d	62	32.0	20	Adjuvant	Depressive disorder	Paroxetine 20 mg	Escitalopram 10 mg	*4/*41 (IM)

BMI body mass index, C _trough trough concentration, CYP cytochrome P450, EM extensive metabolizer, IM intermediate metabolizer, NA not available

^aDiagnosed before initiation of tamoxifen therapy

^bParoxetine and fluoxetine are equally potent inhibitors of CYP2D6 [19]

^cOne woman received citalopram instead of escitalopram; however, the weak CYP2D6-inhibiting properties of the compounds are similar [20]

^dBecause of problems with blood sampling, only C _trough values were available

^eBased on a high BMI